SeaStar Medical Appoints David A. Green as Chief Financial Officer
January 11 2024 - 4:05PM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device
company developing proprietary solutions to reduce the consequences
of hyperinflammation on vital organs, announces the appointment of
healthcare industry veteran David A. Green as Chief Financial
Officer, effective January 10, 2024. Caryl Baron, who has served as
Interim CFO since October 2022, will continue with SeaStar Medical
as Vice President of Finance.
“We welcome David to our executive team at this
critical time as we prepare for our first commercial launch for the
Selected Cytopheretic Device Pediatric (SCD-PED) later this
quarter,” said Eric Schlorff, CEO of SeaStar Medical. “David’s
extensive financial experience at public medical device and
therapeutics companies will be highly valuable as we work to bring
our groundbreaking solutions to those with devastating
hyperinflammation. Importantly, David shares our commitment to
improving patient outcomes and saving lives.
“On behalf of the entire SeaStar Medical team, I
extend our thanks to Caryl for stepping into the CFO position on an
interim basis during our transition to public company status. We
look forward to her continued service to our Company.”
“SeaStar Medical’s cell-directed extracorporeal
therapy holds potential in multiple high-value indications to stop
the threat of a dysregulated inflammatory response that can cause
organ damage and even death, while also reducing healthcare system
costs,” said Mr. Green. “I’m excited to join this talented, focused
and highly motivated team.”
Mr. Green has more than 25 years of financial
experience primarily in the healthcare sector. He previously served
as Interim CFO of Prolacta Bioscience, a private company providing
specialized nutrition products to critically ill premature infants,
where he led efforts to pursue an initial public offering. Prior to
Prolacta, he was Executive Vice President and CFO of Aytu
BioPharma, a publicly traded specialty pharmaceutical and medical
device company marketing prescription and over-the-counter
products. In this position, he completed multiple financing
transactions and was instrumental in the company’s M&A
activities. Earlier, he was Chief Accounting Officer at Intarcia
Therapeutics, a commercial-stage biopharmaceutical company; CFO of
Catheter Connections, a commercial-stage medical device company
acquired by Merit Medical; and CFO of Specialized Health Products
International, a publicly traded medical device company acquired by
C.R. Bard. Since 2014 Mr. Green has provided strategic financial
consulting services to public and private healthcare companies.
Earlier in his career Mr. Green served as
Managing Director at Duff & Phelps, a global investment banking
and corporate finance advisory firm, and as a founding member of
Ernst & Young's Palo Alto Center for Strategic Transactions,
where he advised clients on using strategic transactions to
accelerate growth. Mr. Green holds a BS from the State University
of New York and an MBA from the University of Rochester. He is a
Certified Public Accountant in the State of Illinois.
About SeaStar
MedicalSeaStar Medical is a medical technology
company that is redefining how extracorporeal therapies may reduce
the consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to
provide life-saving solutions to critically ill patients. The
Company is developing and commercializing cell-directed
extracorporeal therapies that target the effector cells that drive
systemic inflammation, causing direct tissue damage and secreting a
range of pro-inflammatory cytokines that initiate and propagate
imbalanced immune responses. For more information visit
https://seastarmedical.com/or visit us on LinkedIn or X (previously
Twitter).
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to the first commercial launch of SeaStar
Medical’s product. Words such as “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside SeaStar Medical’s control and are
difficult to predict. Factors that may cause actual future events
to differ materially from the expected results include, but are not
limited to: (i) the risk that SeaStar Medical may not be able to
obtain regulatory approval of its SCD product candidates; (ii) the
risk that SeaStar Medical may not be able to raise sufficient
capital to fund its operations, including clinical trials; (iii)
the risk that SeaStar Medical and its current and future
collaborators are unable to successfully develop and commercialize
its products or services, or experience significant delays in doing
so, including failure to achieve approval of its products by
applicable federal and state regulators, (iv) the risk that SeaStar
Medical may never achieve or sustain profitability; (v) the risk
that SeaStar Medical may not be able to access funding under
existing agreements, including the equity line of credit and
forward purchase agreements; (vi) the risk that third-parties
suppliers and manufacturers are not able to fully and timely meet
their obligations, (vii) the risk of product liability or
regulatory lawsuits or proceedings relating to SeaStar Medical’s
products and services, (viii) the risk that SeaStar Medical is
unable to secure or protect its intellectual property, and (ix)
other risks and uncertainties indicated from time to time in
SeaStar Medical’s Annual Report on Form 10-K, including those under
the “Risk Factors” section therein and in SeaStar Medical’s other
filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:
LHA Investor RelationsJody Cain(310)
691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Apr 2024 to May 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From May 2023 to May 2024